Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Groupe Oncologie Radiotherapie Tete Cou
Sponsor

Groupe Oncologie Radiotherapie Tete Cou

France 4 B Rue Emile Zola, 37000 Tours, France

About the sponsor

Research activity is centred on head and neck squamous cell carcinoma, including locally advanced, recurrent, and metastatic disease across the oral cavity, oropharynx, hypopharynx, and larynx.

  • Locally advanced squamous cell carcinoma
  • Recurrent or metastatic squamous cell carcinoma
  • Untreated head and neck cancer

The portfolio also includes disease settings defined by platinum-refractory relapse and PD-L1-positive recurrent disease.

About Specializations

Groupe Oncologie Radiotherapie Tete Cou runs clinical trials in conditions such as Squamous cell carcinoma of head and neck, Metastatic squamous cell carcinoma, Squamous cell carcinoma of the hypopharynx, Laryngeal squamous cell carcinoma, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

11 clinical trials

Squamous cell carcinoma of head and neck

Recruiting

A study of ficerafusp alfa and nivolumab in patients with head and neck cancer who did not respond to platinum-based chemotherapy.

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Squamous cell carcinoma of head and neck

Recruiting

Study of ivonescimab alone or with ligufalimab versus pembrolizumab for patients with recurrent or metastatic head and neck squamous cell cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Ivonescimab
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Squamous cell carcinoma of head and neck

Recruiting

Study of avelumab and cetuximab combination treatment after TPEx chemotherapy for patients with recurrent or metastatic head and neck cancer receiving first-line therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Squamous cell carcinoma of head and neck

Not recruiting

Study of pucotenlimab with becotatug vedotin versus becotatug vedotin alone for patients with locally advanced head and neck squamous cell carcinoma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Becotatug vedotin
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Squamous cell carcinoma of head and neck

Not recruiting

Study on the Safety and Tolerance of Durvalumab and Radiotherapy for Patients with Untreated Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Squamous cell carcinoma of head and neck

Not recruiting

Study on Adding Nivolumab to Cisplatin and Radiotherapy for High-Risk Patients with Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Squamous cell carcinoma of head and neck

Not recruiting

Study Comparing Radiotherapy Alone to Radiotherapy with Cisplatin for Patients with Sinus or Salivary Gland Tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Squamous cell carcinoma of head and neck

Not recruiting

Study Comparing Avelumab, Cetuximab, and Radiotherapy with Standard Treatments for Patients with Advanced Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Metastatic squamous cell carcinoma

Not recruiting

Study on Chemotherapy with Cisplatin, Fluorouracil, and Docetaxel for Patients with Locally Advanced Squamous Cell Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Squamous cell carcinoma of the hypopharynx+1

Not recruiting

Study on Preserving the Voice Box in Patients with Advanced Laryngeal or Hypopharyngeal Cancer Using Cisplatin, Fluorouracil, and Docetaxel Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Head and neck cancer

Not recruiting

Study of Radiotherapy with Cetuximab and Xevinapant for Patients with Advanced Head and Neck Cancer Unfit for High-Dose Cisplatin

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.